Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Age-related Macular Degeneration, Geographic Atrophy

In brief

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

Key facts

Study ID

NCT05380492

Run by

Perceive Biotherapeutics, Inc.

People needed

45

Starts

2022-11-17

Expected to finish

2025-11-01

Last updated by the study team

2024-04-11

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are ≥50 years of age at the time of consent.
• Are willing and able to understand and provide written informed consent.
• Are willing and able to return for scheduled treatment and follow-up examinations.
• Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
• Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV.
• Absence of signs of non-exudative MNV.
• Additional Ocular Inclusion Criteria
• Meet certain genotype criteria for risk of AMD.

You may not qualify if…

• Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
• Additional Systemic, Ocular, and Genetic Exclusion Criteria.

Where it is running

• Ophthalmic Consultants of Boston — Boston, Massachusetts, United States
• Retina Consultants of Texas — Bellaire, Texas, United States
• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.